Proteome Sciences has developed in-vitro assays to treat skin and respiratory system allergies induced by chemical compounds and substances.
As part of the invitation request, Proteome Sciences joined the Sens-it-iv project in 2009 to introduce a new proteomic biomarker approach to allergy testing.
By using PS Biomarker Services platform, Proteome identified and filed patents for over 100 biomarkers from cells in the immune system and more than 100 more from skin cells.
Proteome Sciences chief executive Christopher Pearce said they selected eight of these and developed TMT-SRM assays in just four weeks and these have shown excellent results.
"Most importantly, the biomarker assays developed provide an ‘in-vitro’ alternative to animal testing that will become mandatory across the EU," Pearce said.